Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Companyâ€™s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patientâ€™s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	1.16M 1.01M 934K 875K 1.64M 109M 1.65M 11.09M 4.3M 53.77M 4.35M 4.25M 187M	P/E 2024	-2.41x	P/E 2025	-3.27x
Enterprise Value	1.24M 1.08M 998K 936K 1.75M 117M 1.77M 11.85M 4.59M 57.49M 4.65M 4.55M 200M	EV / Sales 2024	497x	EV / Sales 2025	-
Free-Float	83.91%	Yield 2024 *	-	Yield 2025	-

21/05	Abpro Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Abpro Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	Abpro Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI
25/02	Abpro Holdings, Inc.(NasdaqCM:ABP) dropped from S&P TMI Index	CI
20/02	Abpro Holdings, Inc.(OTCPK:ABPO) dropped from NASDAQ Composite Index	CI
04/02	Abpro Holdings, Inc. Announces Board and Committee Resignations	CI
24/01	Abpro Holdings, Inc. Announces Board and Committee Changes	CI
17/01	Abpro Holdings, Inc. announced that it expects to receive $0.147 million in funding	CI
07/01	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
06/01	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
15/12	Abpro Holdings announces submission of an IND application to initiate a Phase 1 clinical trial of T cell engager ABP-102/CT-P72 for HER2-positive cancers	RE
15/12	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI
15/11	Abpro Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

15/01	Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference	AQ
06/01	Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	AQ
15/12	Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers	AQ
09/12	Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives	AQ
05/11	Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABPRO CORPORATION	-.--%	-.--%	-	-	1.16M
LONZA GROUP AG	+1.44%	+1.71%	-10.63%	-9.16%	43.13B
REVOLUTION MEDICINES, INC.	+3.31%	+5.93%	+308.19%	+562.02%	34.65B
BEONE MEDICINES AG	+2.84%	+2.14%	+6.87%	+34.93%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.54%	+8.51%	-22.34%	28B
CELLTRION, INC.	-1.90%	-1.56%	+11.62%	+19.80%	24.45B
ASCENDIS PHARMA A/S	-0.14%	+5.86%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-1.53%	+52.04%	+107.47%	13.14B
EUROFINS SCIENTIFIC SE	-0.57%	-2.43%	+5.18%	+4.20%	12.53B
IONIS PHARMACEUTICALS, INC.	-0.26%	+1.15%	+100.27%	+80.69%	12.25B
Average	+0.37%	+0.73%	+60.26%	+97.20%	23.61B
Weighted average by Cap.	+0.77%	+1.27%	+65.22%	+113.23%

	2024	2025
Net sales	183K 160K 148K 138K 259K 17.26M 261K 1.75M 679K 8.5M 687K 672K 29.51M	-
Net income	-7.23M -6.31M -5.83M -5.47M -10.23M -682M -10.32M -69.24M -26.83M -336M -27.14M -26.56M -1.17B	-2.89M -2.52M -2.33M -2.19M -4.09M -273M -4.12M -27.69M -10.73M -134M -10.85M -10.62M -466M
Net Debt	478K 417K 385K 361K 676K 45.08M 682K 4.58M 1.77M 22.19M 1.79M 1.76M 77.09M	80K 69.76K 64.51K 60.46K 113K 7.54M 114K 766K 297K 3.71M 300K 294K 12.9M

Abpro Corporation Stock Nasdaq

Stocks

US0008501076

Biotechnology & Medical Research

Valuation: Abpro Corporation

Latest news : Abpro Corporation

Press Releases: Abpro Corporation

Other Biotechnology & Medical Research

Financials

Company Profile